Obtaining insurance coverage for human growth hormone treatment for Idiopathic Short Stature (ISS)

In 2003, the Food and Drug Administration approved the use of growth hormone (GH) for the long-term treatment of idiopathic short stature (ISS), which refers to extreme short stature that does not have a diagnostic explanation, such as GH deficiency. Unfortunately, GH treatment is expensive and, as a result, insurance companies often resist paying for it.

Follow this link to an article we have prepared which discusses how ISS is defined, how it is diagnosed, how insurance companies try to avoid payment for it and how we respond to the insurance companies’ arguments: http://www.kantorlaw.net/documents/Article-on-HGH-treatment-DJO-4-5-13-pdf.pdf

Contact Information